Attributes | Values |
---|
rdf:type
| |
description
| - wetenschappelijk artikel (nl)
- im Februar 2019 veröffentlichter wissenschaftlicher Artikel (de)
- artículu científicu espublizáu en febreru de 2019 (ast)
- articolo scientifico (pubblicato il 2019) (it)
- artikull shkencor i botuar më 01 shkurt 2019 (sq)
- scientific article published on 01 February 2019 (en)
- գիտական հոդված հրատարակված 2019 թվականի փետրվարի 1-ին (hy)
- наукова стаття, опублікована в лютому 2019 (uk)
|
publication date
| |
publication date
| |
author name string
| |
author name string
| - Alberto Ortiz
- Carmine Zoccali
- Charles J Ferro
- Francesca Mallamaci
- Ziad Massy
- Gérard M London
- Denis Fouque
- Radovan Hojs
- Robert Ekart
- Pantelis Sarafidis
- Khaled Khazim
- Andrej Wiecek
- Petro Ruggenenti
|
rdfs:label
| - SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA (en)
- SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA (nl)
- SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA (sq)
|
skos:prefLabel
| - SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA (en)
- SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA (nl)
- SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA (sq)
|
name
| - SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA (en)
- SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA (nl)
- SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA (sq)
|
author
| |
author
| |
title
| |
title
| - SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA (en)
|
page(s)
| |
page(s)
| |
instance of
| |
instance of
| |
PubMed ID
| |
PubMed ID
| |
PubMed ID
| |
published in
| |
published in
| |
issue
| |
volume
| |
issue
| |
volume
| |
DOI
| |
DOI
| |
DOI
| |
corrigendum / erratum
| |
corrigendum / erratum
| |
is about
of | |
is cites work
of | |
is cites work
of | |
is of
of | |